Sign In
Last checked at 
21 Aug 2017 12:00
21 August 2017
Avacta Group plc
("Avacta", the "Group" or the "Company")
Director/PDMR Shareholding
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, announces that its Chief Executive Officer, Dr Alastair Smith has today purchased 33,225 ordinary shares of 10p each ("Ordinary Shares") at a price of 74.5p per share.
Following this transaction, Dr Smith's total beneficial interest in the Group is 570,509 Ordinary Shares, representing approximately 0.8% of Avacta's issued share capital. In addition, Alastair Smith has a joint interest in 1,640,000 shares in the share capital of the Company; such shares are jointly held by certain Directors individually and Avacta Group Trustee Limited in its capacity as trustee of The Avacta Employees' Share Trust.
Enquiries:
Avacta Group plc Alastair Smith, Chief Executive Officer Tony Gardiner, Chief Financial Officer
| Tel: +44 (0) 844 414 0452 www.avacta.com |
finnCap Ltd Geoff Nash / Giles Rolls - Nominated Adviser Tim Redfern / Alice Lane - Corporate Broking
WG Partners David Wilson Nigel Barnes Claes Spang
| Tel: +44 (0) 207 220 0500 www.finncap.com
Tel: +44 (0) 203 705 9318 Tel: +44 (0) 203 705 9217 www.wgpartners.co.uk
|
Media Enquiries FTI Consulting Simon Conway / Natalie Garland-Collins | Tel: +44 (0) 203 727 1000 avacta@fticonsulting.com |
Notes to Editors
Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.
Antibodies dominate markets worth in excess of $50bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.
Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.
The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1. | Details of the person discharging managerial responsibilities / person closely associated | |||||
a) | Name | Alastair Smith | ||||
2. | Reason for the Notification | |||||
a) | Position/status | Chief Executive Officer | ||||
b) | Initial notification/Amendment |
| ||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Avacta Group Plc | ||||
b) | LEI | n/a | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the Financial instrument, type of instrument |
| ||||
Identification code | GB00BYYW9G87 | |||||
b) | Nature of the transaction |
| ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information: · Aggregated volume · Price |
See above | ||||
e) | Date of the transaction | 21 August 2017 | ||||
f) | Place of the transaction | London Stock Exchange, AIM Market (XLON) | ||||
Follow the stocks
